Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

A reescalating battle between pharmaceutical companies and pharmacy benefit managers is brewing in Washington, D.C., as ...

Principal Securities Inc. grew its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 3.2% during the fourth ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Earnings have fallen but are still strong enough to meet CVS Health's dividend commitment. Management expects adjusted ...

CVS Health stock received a positive adjustment to its Relative Strength (RS) Rating, from 70 to 73. Please watch the video ...

Our drive to greater drug pricing transparency through innovation has never been more needed,” Ed DeVaney says.

Ed DeVaney’s promotion is the latest leadership shakeup at CVS Health as the company works on a multi-year turnaround plan.

CVS Health (NYSE:CVS – Free Report) had its price target lifted by JPMorgan Chase & Co. from $80.00 to $81.00 in a report ...

We recently compiled a list of the 10 Best Performing S&P 500 Stocks So Far in 2025. In this article, we are going to take a ...

Retail pharmacy chain CVS Health (CVS) is scheduled to announce its results for the fourth quarter of 2024 before the market ...